Zhen Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhen Zhang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chunrong Li
University of Wisconsin-Madison
1 shared publication - Hao Chang
University of Wisconsin-Madison 1 Department of Dermatology Madison, WI 53705
1 shared publication - Lingjun Li
University of Wisconsin-Madison
1 shared publication - Matthew E. Brown
Division of Transplantation, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, UW Health Transplant Center, Madison, Wisconsin, USA
1 shared publication - Natalia Del Rio
University of Wisconsin-Madison
1 shared publication - Nina Hawkins
University of Wisconsin-Madison
1 shared publication
Latest Publications
- Open Access
- 6 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Development of Potent and Selective RIPK1 Degraders with In Vivo Efficacy for Cancer Treatment
Receptor-interacting protein kinase 1 (RIPK1) is a threonine/serine kinase that serves as a critical regulator of immune re-sponses and cell death pathways, functioning through both its catalytic kinase activity and non-catalytic scaffold function. The scaffold function of RIPK1 contributes to both intrinsic and extrinsic resistance to immune checkpoint blockades (ICBs), making it a compelling therapeutic target for enhancing cancer immunotherapy. Recent studies have highlighted RIPK1’s potential as a key modulator for improving the efficacy of immune-stimulatory therapies, such as ICBs and radio-therapy. In this study, we have developed a highly potent and selective RIPK1 degrader. Our degrader demonstrated signifi-cant tumor growth suppression when combined with X-ray radiotherapy (XRT), achieving enhanced therapeutic efficacy without adverse effects on body weight. These findings underscore the potential of RIPK1 degradation as a novel approach to augment radiotherapy and advance cancer immunotherapy strategies.
- 6 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDevelopment of Potent and Selective RIPK1 Degraders with In Vivo Efficacy for Cancer Treatment
Receptor-interacting protein kinase 1 (RIPK1) is a threonine/serine kinase that serves as a critical regulator of immune re-sponses and cell death pathways, functioning through both its catalytic kinase activity and non-catalytic scaffold function. The scaffold function of RIPK1 contributes to both intrinsic and extrinsic resistance to immune checkpoint blockades (ICBs), making it a compelling therapeutic target for enhancing cancer immunotherapy. Recent studies have highlighted RIPK1’s potential as a key modulator for improving the efficacy of immune-stimulatory therapies, such as ICBs and radio-therapy. In this study, we have developed a highly potent and selective RIPK1 degrader. Our degrader demonstrated signifi-cant tumor growth suppression when combined with X-ray radiotherapy (XRT), achieving enhanced therapeutic efficacy without adverse effects on body weight. These findings underscore the potential of RIPK1 degradation as a novel approach to augment radiotherapy and advance cancer immunotherapy strategies.